Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2025, Vol. 57 ›› Issue (5): 934-940. doi: 10.19723/j.issn.1671-167X.2025.05.018

Previous Articles     Next Articles

Influence of long-term biologic therapy on metabolic biochemical parameters in moderate to severe plaque psoriasis

Xiangxian LIU1,2, Yi LIN1,2, Jinzhu GUO1,*()   

  1. 1. Department of Dermatology, Peking University Third Hospital, Beijing 100191, China
    2. Peking University Health Science Center, Beijing 100191, China
  • Received:2024-11-12 Online:2025-10-18 Published:2025-08-28
  • Contact: Jinzhu GUO
  • Supported by:
    the National Key Research and Development Program of China(2023YFC2508106); the Beijing Health Promotion Association Medical Science Research Fund(Z2022023058008)

RICH HTML

   

PDF (PC)

Abstract: Objective: To assess the impact of long-term biologic therapy on metabolic biochemical parameters in moderate to severe plaque psoriasis patients. Methods: The study included patients over 18 years old who had been treated by biological agents for at least 24 weeks for moderate to severe plaque psoriasis from Novermber 2015 to January 2024. According to the biological agents the patients used, they were divided into three groups: interleukin-17 (IL-17) inhibitor group, IL-23 and IL-12/23 inhibitor group and tumor necrosis factor-α (TNF-α) inhibitor group. The metabolic biochemical parameters of each group were evaluated and compared before and after the administration of the biologic therapies. Results: A total of 174 patients with moderate to severe plaque psoriasis were included in the long-term treatment with biologics, including 127 males (73.00%), 47 females (27.00%), with a median age of 38.00 (31.50, 49.00) years and a median duration of psoriasis of 12.00 (10.00, 20.00) years. The median duration of biologic treatment was 61.00 (49.00, 96.25) weeks, ranging from 26 to 301 weeks. There were 101 patients in the IL-17 inhibitor group, 38 patients in the IL-23 and IL-12/23 inhibitor group, and 35 patients in the TNF-α inhibitor group. After long-term treatment with IL-17 inhibitors, no statistically significant changes were observed in body weight, body mass index (BMI), alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting glucose (GLU), total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) compared with baseline measurements (P>0.05). However, low-density lipoprotein cholesterol (LDL-C) levels were significantly reduced [(2.90±0.75) mmol/L vs. (3.05±0.79) mmol/L, t=－2.100, P=0.038], while uric acid (UA) levels showed a significant increase [(401.13±99.13) μmol/L vs. (364.94±91.11) μmol/L, t=5.215, P < 0.001]. The group with normal UA levels before treatment showed a significant increase after long-term application of biological agents compared with before treatment [(370.69± 89.59) μmol/L vs. (324.66±64.50) μmol/L, t=5.856, P < 0.001]. Following long-term application of IL-23 and IL-12/23 inhibitors, no statistically significant differences were observed in body weight, BMI, ALT, AST, GLU, TC, TG, HDL-C and UA levels when compared with baseline measurements (P> 0.05). However, LDL-C levels exhibited a significant reduction from baseline [(2.85±0.74) mmol/L vs. (3.12±0.68) mmol/L, t=－2.082, P=0.045]. After long-term treatment with TNF-α inhibitor, there were no significant differences in body weight, BMI, ALT, AST, GLU, TC, TG, HDL-C, LDL-C and UA compared with baseline measurements (P>0.05). Conclusion: Long-term application of IL-17 inhibitors in moderate to severe plaque psoriasis patients may result in elevated uric acid levels, particularly in patients with normal uric acid levels before treatment. The long-term use of IL-17 inhibitors, IL-23 inhibitors or IL-12/23 inhibitors might reduce LDL-C levels.

Key words: Psoriasis, Biologics, Metabolic, Retrospective study

CLC Number: 

  • R758.63

Table 1

Comparison among IL-17 inhibitors group, IL-23 & IL-12/23 inhibitors group, and TNF-α inhibitors group at baseline"

Items IL-17 (n=101) IL-23 & IL-12/23 (n=38) TNF-α (n=35) F/H/χ2 P
Psoriasis duration/years 12.00 (8.50, 20.50) 12.50 (9.75, 18.50) 12.50 (10.00, 20.00) 0.721b 0.697
Duration of treatment/weeks 64.00 (90.00, 91.50) 58.00 (49.00, 95.00) 55.00 (40.00, 105.00) 0.309b 0.857
Age/years 38.00 (31.50, 51.00) 37.00 (31.00, 45.50) 39.00 (32.00，51.00) 1.281b 0.527
Male 72 (71.3) 26 (68.4) 29 (82.9) 1.135c 0.324
Weight at baseline/kg 74.07±15.15 70.87±15.06 73.05±14.73 0.881a 0.417
BMI at baseline/(kg/m2) 25.11±4.08 24.45±3.86 24.70±4.26 2.855a 0.063
ALT at baseline/(U/L) 22.00 (13.00, 37.25) 19.00 (13.50, 31.50) 26.00 (13.00, 36.00) 0.425b 0.809
ALT elevated cases 21 (21.9) 6 (17.1) 7 (20.0) 0.359c 0.836
AST at baseline/(U/L) 21.00 (18.00, 29.00) 21.00 (17.50, 25.50) 24.54±7.36 1.241b 0.538
AST elevated cases 5 (5.2) 2 (5.7) 2 (5.7) 0.020c 0.990
GLU at baseline/(mmol/L) 5.40 (4.90, 5.70) 5.40 (5.05, 5.80) 5.48±0.78 0.754b 0.686
GLU elevated cases 14 (14.9) 7 (20.6) 4 (14.3) 0.678c 0.712
TC at baseline/(mmol/L) 4.74±0.95 4.94±0.88 4.76±0.94 0.502a 0.606
TC elevated cases 29 (30.5) 15 (40.5) 9 (29.0) 1.429c 0.490
TG at baseline/(mmol/L) 1.38 (0.91, 2.19) 1.22 (0.77, 2.10) 1.40 (0.94, 1.85) 0.461b 0.794
TG elevated cases 33 (34.4) 17 (45.9) 12 (38.7) 1.534c 0.464
HDL-C at baseline/(mmol/L) 1.11 (0.98, 1.32) 1.15 (1.02, 1.40) 1.19±0.26 1.479b 0.477
HDL-C lowered cases 37 (38.5) 10 (27.0) 8 (25.8) 2.613c 0.271
LDL-C at baseline/(mmol/L) 3.05±0.79 3.12±0.68 3.30 (2.56, 3.68) 0.947b 0.623
LDL-C elevated cases 22 (23.2) 9 (24.3) 9 (29.0) 0.437c 0.804
UA at baseline/(μmol/L) 364.94±91.11 367.78±101.13 406.34±110.71 1.805a 0.168
UA elevated cases 24 (25.3) 12 (33.3) 12 (41.3) 2.994c 0.224

Table 2

Changes in metabolic biomarkers before and after IL-17 inhibitor therapy"

Items n At baseline After treatment t/Z P
Weight/kg 78 74.07±15.15 74.79±14.55 1.260a 0.211
BMI/(kg/m2) 78 25.11±4.08 25.38±4.02 1.452a 0.151
ALT/(U/L) 96 22.00(13.00, 37.25) 23.00(15.75, 42.25) -1.901b 0.057
AST/(U/L) 96 21.00(18.00, 29.00) 23.00(18.00, 30.25) -1.730b 0.084
GLU/(mmol/L) 94 5.40(4.90, 5.70) 5.30(5.00, 5.75) -0.410b 0.682
TC/(mmol/L) 95 4.74±0.95 4.64±0.97 -1.052a 0.295
TG/(mmol/L) 96 1.38(0.91, 2.19) 1.35(1.01, 1.87) -0.226b 0.821
HDL-C/(mmol/L) 96 1.11(0.98, 1.32) 1.11(0.94, 1.29) -1.128b 0.259
LDL-C/(mmol/L) 95 3.05±0.79 2.90±0.75 -2.100a 0.038
UA/(μmol/L) 95 364.94±91.11 401.13±99.13 5.215a ＜0.001

Table 3

Changes in metabolic biomarkers before and after IL-23 & IL-12/23 inhibitor therapy"

Items n At baseline After treatment t/Z P
Weight/kg 26 70.87±15.06 71.37±14.40 0.953a 0.350
BMI/(kg/m2) 26 24.45±3.86 24.65±3.71 1.119a 0.274
ALT/(U/L) 35 19.00 (13.50, 31.50) 21.00 (16.00, 36.75) -0.659b 0.510
AST/(U/L) 35 21.00 (17.50, 25.50) 22.00 (19.00, 28.50) -1.065b 0.287
GLU/(mmol/L) 34 5.40 (5.05, 5.80) 5.40 (5.10, 5.80) -0.236b 0.814
TC (mmol/L) 37 4.94±0.88 4.77±0.76 -1.454a 0.155
TG/(mmol/L) 37 1.22 (0.77, 2.10) 1.23 (0.84, 2.04) -0.158b 0.874
HDL-C/(mmol/L) 37 1.15 (1.02, 1.40) 1.19 (1.00, 1.34) -0.883b 0.377
LDL-C/(mmol/L) 37 3.12±0.68 2.85±0.74 -2.082a 0.045
UA/(μmol/L) 36 367.78±101.13 371.00±91.79 0.287a 0.768

Table 4

Changes in metabolic biomarkers before and after TNF-α inhibitor therapy"

Items n At baseline After treatment t/Z P
Weight/kg 31 73.05±14.73 73.77±14.73 1.160a 0.255
BMI/(kg/m2) 31 24.70±4.26 24.96±4.31 1.252a 0.220
ALT/(U/L) 35 26.00(13.00, 36.00) 25.00(18.00, 31.00) -0.094b 0.925
AST/(U/L) 35 24.54±7.36 22.00(18.00, 29.00) -0.322b 0.747
GLU/(mmol/L) 28 5.48±0.78 5.40(5.00, 6.10) -0.013b 0.990
TC/(mmol/L) 31 4.76±0.94 4.72±0.88 -0.282a 0.780
TG/(mmol/L) 31 1.40(0.94, 1.85) 1.70±0.86 0.075a 0.940
HDL-C/(mmol/L) 31 1.19±0.26 1.13(1.01, 1.26) -1.358b 0.174
LDL-C/(mmol/L) 31 3.30(2.56, 3.68) 3.08±0.81 -0.392b 0.695
UA/(μmol/L) 29 406.34±110.71 378.14±77.45 -1.572a 0.127

Table 5

Changes in uric acid levels before and after IL-17 inhibitors therapy"

Items n At baseline After treatment t P
Normal uric acid group/(μmol/L) 71 324.66±64.50 370.69±89.59 5.856 ＜0.001
Male in normal uric acid group/(μmol/L) 46 353.35±51.08 406.74±81.34 4.930 ＜0.001
Female in normal uric acid group/(μmol/L) 25 271.88±52.66 304.36±62.69 3.329 0.003
High uric acid group/(μmol/L) 24 489.08±38.01 491.17±66.44 0.538 0.596

Table 6

Analysis of influencing factors of uric acid level before and after IL-17 inhibitors therapy"

Items Ixekizumab Secukinumab
n r P n r P
Age 21 -0.185 0.423 74 -0.014 0.909
Gender 21 0.382 0.087 74 -0.003 0.977
Duration of treatment 21 0.267 0.242 74 0.027 0.819
1
中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2023版)[J]. 中华皮肤科杂志, 2023, 56(7): 573- 625.
2
Smith CH, Yiu ZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update[J]. Br J Dermatol, 2020, 183(4): 628- 637.

doi: 10.1111/bjd.19039
3
Chen L, Shen Z. Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders[J]. Cell Mol Immunol, 2020, 17(1): 64- 75.

doi: 10.1038/s41423-019-0291-4
4
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南(2021)[J]. 中华皮肤科杂志, 2021, 54(12): 1033- 1047.
5
Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities[J]. J Am Acad Dermatol, 2019, 80(4): 1073- 1113.

doi: 10.1016/j.jaad.2018.11.058
6
Blauvelta A, Armstrong AW, Langley RG, et al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: Results from the ECLIPSE study[J]. J Dermatolog Treat, 2022, 33(4): 2317- 2324.

doi: 10.1080/09546634.2021.1959504
7
Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase Ⅱ dose-ranging study[J]. Br J Dermatol, 2013, 168(2): 412- 421.

doi: 10.1111/bjd.12110
8
Reich K, Puig L, Mallbris L, et al. The effect of bodyweight on the efficacy and safety of ixekizumab: Results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis[J]. J Eur Acad Dermatol Venereol, 2017, 31(7): 1196- 1207.

doi: 10.1111/jdv.14252
9
Zhao Z, Cai L, Zhang S, et al. Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis[J]. Chin Med J (Engl), 2022, 135(12): 1438- 1443.

doi: 10.1097/CM9.0000000000002130
10
方宁远, 吕力为, 吕晓希, 等. 中国高尿酸血症相关疾病诊疗多学科专家共识(2023年版)[J]. 中国实用内科杂志, 2023, 43(6): 461- 480.
11
Montaudié H, Albert-Sabonnadière C, Acquacalda E, et al. Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: Results of a prospective longitudinal observational study[J]. J Eur Acad Dermatol Venereol, 2014, 28(9): 1186- 1191.

doi: 10.1111/jdv.12255
12
Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)[J]. Lancet, 2008, 371(9625): 1675- 1684.

doi: 10.1016/S0140-6736(08)60726-6
13
Martínez-Abundis E, Reynoso-von Drateln C, Hernández-Salazar E, et al. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus[J]. Arch Dermatol Res, 2007, 299(9): 461- 465.

doi: 10.1007/s00403-007-0784-3
14
Merola JF, McInnes IB, Deodhar AA, et al. Effect of secuki-numab on traditional cardiovascular risk factors and inflammatory biomarkers: Post hoc analyses of pooled data across three indications[J]. Rheumatol Ther, 2022, 9(3): 935- 955.

doi: 10.1007/s40744-022-00434-z
15
Wang HN, Huang YH. Changes in metabolic parameters in psoriatic patients treated with secukinumab[J]. Ther Adv Chronic Dis, 2020, 11, 204062232094477.
16
Ehsani AH, Mortazavi H, Balighi K, et al. Changes in body mass index and lipid profile in psoriatic patients after treatment with standard protocol of infliximab[J]. Acta Med Iran, 2016, 54(9): 570- 575.
17
Hagion T, Saeki H, Fujimoto E, et al. Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis[J]. J Clin Med, 2023, 12(5): 1934.

doi: 10.3390/jcm12051934
18
Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S)[J]. J Invest Dermatol, 2020, 140(9): 1784- 1793. e2.

doi: 10.1016/j.jid.2020.01.025
19
Gisondi P, Bellinato F, Bruni M, et al. Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome[J]. Dermatol Ther, 2020, 33(6): e14281.
20
Gerdes S, Pinter A, Papavassilis C, et al. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients[J]. J Eur Acad Dermatol Venereol, 2020, 34(3): 533- 541.

doi: 10.1111/jdv.16004
21
Egeberg A, Wu JJ, Korman N, et al. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3[J]. J Am Acad Dermatol, 2018, 79(1): 104- 109. e8.

doi: 10.1016/j.jaad.2018.02.074
22
Piros ÉA, Szabó Á, Rencz F, et al. Anti-interleukin-17 therapy of severe psoriatic patients results in an improvement of serum lipid and inflammatory parameters' levels, but has No effect on body composition parameters[J]. Life (Basel), 2021, 11(6): 535.
23
Cao H, Su S, Yang Q, et al. Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients[J]. Lipids Health Dis, 2021, 20(1): 16.

doi: 10.1186/s12944-021-01441-9
24
Al-Harbi NO, Nadeem A, Al-Harbi MM, et al. Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model[J]. Immunobiology, 2017, 222(2): 128- 136.

doi: 10.1016/j.imbio.2016.10.013
25
Karataş A, Gerçek AN, Öz B, et al. The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis[J]. Eur J Rheumatol, 2020, 7(4): 169- 172.

doi: 10.5152/eurjrheum.2020.20109
26
Tamer F, Edek YC, Aksakal AB. Does biological agent treatment have an impact on serum uric acid levels in patients with psoriasis?[J]. Curr Med Res Opin, 2023, 39(10): 1297- 1302.

doi: 10.1080/03007995.2023.2260304
27
朱冠男, 徐峰, 俞晨, 等. 对中国皮肤科医生关于饮食影响银屑病的认知调查: 一项横断面分析[J]. 中华皮肤科杂志, 2021, 54(10): 891- 897.
[1] Shuhan YANG, Yixin LI, Haoliang CUI, Youxin WANG, Yuying WU, Mingyue WANG, Yifan YANG, Nur Enkar, Lei YANG, Hui WANG. Associations of metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk factor abnormalities with adverse pregnancy outcomes [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 487-495.
[2] Shengqi ZHENG,Tianchi HUA,Guicao YIN,Wei ZHANG,Ye YAO,Yifan LI. Association between the triglyceride-glucose index and the incidence of nephrolithiasis in male individuals [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 610-616.
[3] Zuhong ZHANG,Tianjiao CHEN,Jun MA. Associations between puberty timing and cardiovascular metabolic risk factors among primary and secondary students [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 418-423.
[4] Yifan WU,Yingxiang YU,Lan XIE,Zhida ZHANG,Cuiqing CHANG. Characteristics of resting energy expenditure and evaluation of prediction formulas in young men with different body mass indexes [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 247-252.
[5] Meng-jie CUI,Qi MA,Man-man CHEN,Tao MA,Xin-xin WANG,Jie-yu LIU,Yi ZHANG,Li CHEN,Jia-nuo JIANG,Wen YUAN,Tong-jun GUO,Yan-hui DONG,Jun MA,Yi XING. Association between different growth patterns and metabolic syndrome in children and adolescents aged 7 to 17 years [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 415-420.
[6] Mei-ni ZUO,Yi-qing DU,Lu-ping YU,Xiang DAI,Tao XU. Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 636-643.
[7] Yu-hui LI,Bo SU,Fu-an LIN,Ya-nan FEI,Xiao-xia YU,Wen-qiang FAN,Hai-ying CHEN,Xue-wu ZHANG,Yuan JIA. Cross-sectional study on clinic behavior and therapeutic status of patients with psoriatic arthritis in multi-center [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1014-1018.
[8] HE Liu, TANG Xun, HU Yong-hua. Relationship of menopause with cardiovascular disease and related metabolic disorders [J]. Journal of Peking University(Health Sciences), 2016, 48(3): 448-453.
[9] LIU Miao, HE Yao, JIANG Bin, WU Lei, WANG Jian-Hua, YANG Shan-Shan, WANG Yi-Yan, LI Xiao-Ying. Relationship between brachial-ankle pulse wave velocity and metabolic syndrome among the elderly in a Beijing community and the gender difference [J]. Journal of Peking University(Health Sciences), 2014, 46(3): 429-434.
[10] YAN Rui, LUAN Qing-Xian, LIU Li-Sheng, WANG Xing-Yu, LI Peng, SHA Yue-Qin. Association between chronic periodontitis and metabolic syndrome related mitochondria single nucleotide polymorphism [J]. Journal of Peking University(Health Sciences), 2014, 46(2): 264-268.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd